ArticleFrontiers in veterinary science2025
Bone marrow toxicity associated with febantel administration in a dog: Case Report.
Article in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The objective of this case report is to describe a case of bone marrow suppression suspected to be secondary to febantel administration in a dog. Case summary: A 6-year-old neutered male Labrador Retriever was presented for lethargy and fever 15 days after receiving oral febantel. Pancytopenia was noted, and bone marrow sampling was consistent with hypoplasia suspected to be due to the febantel administration as no other toxic insults were identified. The dog made a full recovery in approximately 2 weeks after stopping the febantel. Discussion: This is the first report of suspected bone marrow toxicity secondary to febantel administration. Febantel is metabolized to fenbendazole, which has been documented as causing bone marrow toxicity in canines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.